Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Remdesivir effective, well-tolerated in final trial report

Key clinical point: In addition to the primary endpoint of time to recovery, remdesivir shortened hospital stay and reduced time on oxygen.

Major finding: The 5-day faster recovery on remdesivir versus placebo (10 vs. 15 days; P less than 0.001) was echoed in multiple secondary endpoints.

Data Source: Double blind, multicenter, placebo-controlled randomized trial.

Disclosures: Dr. Beigel, the principal investigator of this trial, reports no potential conflicts of interest.


Beigel JH et al. N Engl J Med. 2020 Oct 8. doi: 10.1056/NEJMoa2007764.